Loading data for CORT — first visit, this takes a few seconds.

알림

Corcept Therapeutics (CORT)

NasdaqCM: CORT · 실시간 가격 · USD

118.10

+0.93 (0.79%)

종가 기준: Aug 19, 2026, 1:47 PM

0.79% (1D)

데이터 없음

매수호가	109.92
시가총액	13.03B
매출 (ttm)	830.81M
순이익 (ttm)	54.27M
베타	0.46
EPS (ttm)	0.45
P/E (ttm)	267.78
선행 P/E	27.37
P/B (ttm)	18.43
P/S (ttm)	15.68
Earnings Date	Nov 4, 2026

매도호가	116.64
거래량	776,197
평균 거래량 (20일)	1,108,004
시가	116.59
전일 종가	117.17
일중 범위	116.59 - 119.95
52주 범위	28.66 - 122.21
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CORT 소개

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Apr 14, 2004

직원 수 730

상장 거래소 NasdaqCM

티커 CORT

웹사이트 https://www.corcept.com

전체 기업 정보

재무 실적

2025년 Corcept Therapeutics의 매출은 761.41M로, 전년 675.04M 대비 12.79% 증가했습니다. 순이익은 99.65M로, -29.43% 감소했습니다.

재무제표

어닝 서프라이즈

Corcept Therapeutics가 Jul 29, 2026에 분기 실적을 발표했습니다:

매출 $256.15M 예상치 하회 $0, 및 31.74% 전년 대비 성장.

EPS 0.36 예상치 상회 0.30, 및 24.14% 전년 대비 성장.

다음 실적 발표

Corcept Therapeutics의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · StockStory

1 Surging Stock to Own for Decades and 2 We Brush Off

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or ...

1주 전 · Simply Wall St.

Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales

Corcept Therapeutics stock has delivered a very strong run over the past few years, yet its low overall value score suggests the current share price may already reflect a lot of optimism. After such a...

1주 전 · Barchart

Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation

Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year. CORT’s fundamentals are robust with revenue and earnings both projected to grow thi...

2주 전 · Trefis

What IJR's Own History Says About Its Price Today

This popular small-cap fund is trading at a premium to its own history, forcing a hard look at whether the growth inside is enough to justify the price.

2주 전 · Stocktwits

These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months

Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.

2 페이지 중 1

Corcept Therapeutics (CORT)